Showing 6611-6620 of 9762 results for "".
- Experts React to FDA Approval of Cabtreo Topical Gel for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-cabtreo-topical-gel-for-acne-vulgaris/2462087/The U.S. Food and Drug Administration (FDA) has approved CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel for the topical treatment of acne vulgaris in patients aged 12 and older. Bausch Health and Ortho Dermatologics' CABTREO is the first and
- Almirall Seeks Proposals to Better Understand Key Pathological Mechanisms of Skin Diseaseshttps://practicaldermatology.com/news/almirall-seeks-proposals-to-better-understand-key-pathological-mechanisms-of-skin-diseases/2462090/Almirall S.A. is calling for proposals to better understand key pathological mechanisms of several skin diseases through AlmirallShare, its open innovation platform. Almirall’s objective through this call is to identify and explore, through collaboration w
- ESMO News: Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%https://practicaldermatology.com/news/esmo-news-major-pathologic-response-to-neoadjuvant-pembrolizumab-in-advanced-melanoma-trial-exceeds-50/2462089/In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other re
- Aquaphor Partners with NBCUniversal and Giselle Blondet for New Campaignhttps://practicaldermatology.com/news/aquaphor-partners-with-nbcuniversal-and-telemundo-personality-giselle-blondet-for-new-campaign/2462084/Aquaphor is partnering with NBCUniversal and Telemundo personality Giselle Blondet to showcase the multiple uses of Aquaphor Baby Healing Ointment across generations. "Aquaphor Baby has been part of our family for many years. What you see is a perfect reflection of my rel
- Four Grants Awarded by the GW/Pfizer Global Medical Collaborative Grant Program to Establish Teledermatology Programs in Underserved Communities Across the UShttps://practicaldermatology.com/news/four-grants-awarded-by-the-gwpfizer-global-medical-collaborative-grant-program-to-establish-teledermatology-programs-in-underserved-communities-across-the-us/2462080/The George Washington University (GW) School of Medicine and Health Sciences (SMHS), in collaboration with Pfizer Global Medical Grants, announced the four institutions that will be awarded grants to implement GW’s Teledermatology clinic model in underserved areas across the United States.&
- FDA Approves UCB’s BIMZELX for the Treatment of Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ucbs-bimzelx-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis/2462079/The U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Bimekizumab is the first and only approved psoriasis treatment desi
- IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanomahttps://practicaldermatology.com/news/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination-in-gnaq11-metastatic-cutaneous-melanoma/2462076/IDEAYA Biosciences, Inc. is initiating of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma. There are currently no U.S Food and Drug Administration-approved therapies for this genetically-defined patient population. Darova
- Almost Half of All Skin Disease Patients Report Sleep Issueshttps://practicaldermatology.com/news/almost-half-of-all-skin-disease-patients-report-sleep-issues/2462075/Almost half of all patients with skin disease report sleep disturbances, finds new research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The ALL PROJECT analyzed data on more than 50,000 adults across 20 countries to assess the impact
- FDA Approves BMS’ Opdivo (Nivolumab) for Adjuvant Treatment of Eligible Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/fda-approves-bms-opdivo-nivolumab-for-adjuvant-treatment-of-eligible-patients-with-completely-resected-stage-iib-or-iic-melanoma/2462074/The U.S. Food and Drug Administration (FDA) has given its nod to Opdivo (nivolumab) for the adjuvant treatment of eligible adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma. This approval was based on the Phase 3
- Dermavant’s VTAMA Rapidly Eases Itch in ADhttps://practicaldermatology.com/news/dermavants-vtama-rapidly-eases-itch-in-ad/2462065/Dermavant’s VTAMA (tapinarof) Cream, 1% reduces pruritus in adults and kids with atopic dermatitis as early as 24 hours after the first application, according to new data from ADORING 1 and ADORING 2 presented at the European Academy of Dermatology and Venereology (